資元堂生物股份有限公司 資元堂生物股份有限公司 資元堂生物股份有限公司 資元堂生物股份有限公司
  • About Us
  • Studies
  • News
  • Contact Us
  • English
    • English
    • 中文
  • Pipeline
  • Accomplishment
    Patent rewards: Applications in
    type 2 diabetes and diabetic
    wound healing.
    USPTO
    - US 9,655,891 B1 USE OF ISOQUINOLINE DERIVATIVES FOR
    DIABETIC WOUND HEALING
    - US 9,707,222 B2 ISOQUINOLINEALKALOID DERIVATIVE FOR
    ACTIVATING AMP-DEPENDENT PROTEINKINASE
  • 1. GYT002 effectively decreases hepatic glucose for
    type II DM through low dose. Fitting the potential
    hypoglycemic agent invention trend for type II DM.。

    2. GYT005, derived from GYT002, is highly efficiency
    for wound-healing on diabetes.
    The market value of GYT005 for wound-healing on
    diabetes is estimated for US$10 billion per year.

    The revenues of GYT002 and GYT005 are both
    estimated to be at least 4 billion USD in new drugs
    market per year.
    Investments and related disease association are
    welcomed.
    For more informationvia: zytbiotec@gmail.com
    Market Value
  • R&D partnership
    •National Taiwan University, College of Medicine
    In last decade we have collaborated with the
    •Taipei Medical University
    following medical institutions:
    •Development Center for Biotechnology
    •Fu Jen Catholic University, College of Medicine
  • Participated in Bio Taiwan Exhibition
    Participated in Bio Taiwan Exhibition
    Visited Guangzhou University of
    Chinese Medicine
    2017
    2017
    2006